What Does Economic Evaluation Mean in the Context of Children at the End of Their Life?
cost effectiveness analysis
economic evaluation
end of life
health economics
impact inventory
paediatric
palliative
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
03 11 2021
03 11 2021
Historique:
received:
11
10
2021
revised:
29
10
2021
accepted:
02
11
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
19
11
2021
Statut:
epublish
Résumé
The 'conventional framework' of economic evaluation, the comparative public sector healthcare costs and quality adjusted life year (QALY) of two or more interventions, has become synonymous with commissioning decisions in many countries. However, while useful as a framework in guiding value-based decisions, it has limited relevance in areas such as end of life care in children and young people, where the costs fall across multiple stakeholders and QALY gains are not the primary outcome. This paper makes the case that the restricted relevance of the 'conventional framework' has contributed to the inconsistent and varied provision of care in this setting, and to the knock-on detrimental impact on children nearing the end of their lives as well as their families. We explore the challenges faced by those seeking to conduct economic evaluations in this setting alongside some potential solutions. We conclude that there is no magic bullet approach that will amalgamate the 'conventional framework' with the requirements of a meaningful economic evaluation in this setting. However, this does not imply a lack of need for the summation of the costs and outcomes of care able to inform decision makers, and that methods such as impact inventory analysis may facilitate increased flexibility in economic evaluations.
Identifiants
pubmed: 34770074
pii: ijerph182111562
doi: 10.3390/ijerph182111562
pmc: PMC8582854
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute for Health Research
ID : NIHR129213
Organisme : National Institute for Health Research
ID : CDF-2018-11-ST2-002
Références
Health Econ. 2021 Nov;30(11):2847-2857
pubmed: 34455657
Health Econ. 1997 Mar-Apr;6(2):117-32
pubmed: 9158965
Appl Health Econ Health Policy. 2019 Oct;17(5):577-590
pubmed: 31098947
Eur J Health Econ. 2009 Oct;10(4):357-9
pubmed: 19618224
Int J Health Serv. 1991;21(2):365-9; discussion 371-2
pubmed: 2071313
BMC Med Ethics. 2015 Mar 07;16:14
pubmed: 25885447
Palliat Med. 2017 Sep;31(8):716-725
pubmed: 28434392
Palliat Med. 2019 Sep;33(8):1058-1068
pubmed: 31185812
Soc Sci Med. 2021 May;277:113892
pubmed: 33882440
Palliat Med. 2019 Jul;33(7):823-831
pubmed: 30916615
J Fam Psychol. 2008 Apr;22(2):203-11
pubmed: 18410207
Health Policy. 1989 Oct;13(1):19-34
pubmed: 10313378
J Health Econ. 1988 Sep;7(3):289-90
pubmed: 10291478
Ann Palliat Med. 2018 Oct;7(Suppl 3):S244-S248
pubmed: 30180732
J Palliat Care. 2011 Summer;27(2):126-33
pubmed: 21805947
Palliat Med. 2020 Jan;34(1):69-82
pubmed: 31854213
Arch Dis Child. 2001 Mar;84(3):205-11
pubmed: 11207164
J Health Econ. 2012 May;31(3):521-7
pubmed: 22591713
Arch Dis Child Educ Pract Ed. 2018 Dec;103(6):296-299
pubmed: 29434021
Value Health. 2021 May;24(5):691-698
pubmed: 33933238
Br J Clin Pharmacol. 2012 Jun;73(6):855-60
pubmed: 22404227
Eur J Health Econ. 2019 Aug;20(6):779-784
pubmed: 30617754
BMJ Support Palliat Care. 2021 Sep;11(3):296-298
pubmed: 33685946
Expert Rev Pharmacoecon Outcomes Res. 2014 Aug;14(4):473-82
pubmed: 24784902
Appl Health Econ Health Policy. 2020 Jun;18(3):351-356
pubmed: 31797329
BMC Palliat Care. 2013 Apr 25;12(1):18
pubmed: 23617814